Dr. Hudson has received research grant support from Forest Laboratories, Eli Lilly and Company and Ortho-McNeil Neurologies. He has served on advisory boards for Eli Lilly and Pfizer. Dr. Brennan has received research grant support from Eli Lilly. Dr. Jonas is currently an employee of Isis Pharmaceuticals; however, at the time of study design and initiation, he was an employee of Forest Laboratories. The other authors have no relevant disclosures.
Memantine in the treatment of binge eating disorder: An open-label, prospective trial†
Article first published online: 23 APR 2008
Copyright © 2008 Wiley Periodicals, Inc.
International Journal of Eating Disorders
Volume 41, Issue 6, pages 520–526, September 2008
How to Cite
Brennan, B. P., Roberts, J. L., Fogarty, K. V., Reynolds, K. A., Jonas, J. M. and Hudson, J. I. (2008), Memantine in the treatment of binge eating disorder: An open-label, prospective trial. Int. J. Eat. Disord., 41: 520–526. doi: 10.1002/eat.20541
- Issue published online: 8 AUG 2008
- Article first published online: 23 APR 2008
- Manuscript Accepted: 25 FEB 2008
- Forest Laboratories (Investigator-Initiated Trial)
- binge eating disorder;
To assess preliminarily the efficacy of memantine in binge eating disorder.
This was an open-label, 12-week, flexible-dose (5–20 mg/day) trial of memantine in binge eating disorder. The primary outcome was frequency of binge days. Secondary outcomes included frequency of binge episodes, body-mass index (BMI), weight, Clinical Global Impressions Severity (CGI-S), Three Factor Eating Questionnaire (TFEQ), Montgomery–Asberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), and Sheehan Disability Scale (SDS). Longitudinal random regression analysis was performed for frequency of binge days and episodes, BMI, weight, and CGI-S; analysis of baseline to endpoint change was performed for all outcomes.
Sixteen individuals received memantine; 15 completed at least one postbaseline evaluation, 9 completed the study. Mean dose at endpoint was 18.3 mg/day. Memantine was associated with significant reductions in frequency of binge days and episodes, severity of illness (p < .001 for both analyses), disinhibition on the TFEQ (p = .015), and disability on the SDS (p < .05 for three subscales). There was no significant change in BMI, weight, MADRS, HAM-A, and TFEQ cognitive restraint and hunger.
In this open-label trial, memantine was well tolerated and effective in reducing binge eating, severity of illness, and disability, but had little effect on BMI and weight. © 2008 by Wiley Periodicals, Inc. Int J Eat Disord 2008